CNTB - Why Is Skin Disease-Focused Connect Biopharma Stock Lower Today? | Benzinga
Connect Biopharma Holdings Limited (NASDAQ: CNTB) released topline results from Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's (formerly known as CBP-201) efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD).
These results follow the previously reported Stage 1 trial results, which met all primary and key secondary endpoints.
In Stage 2, patients who achieved EASI-50 (responders) regardless of initial treatment in the 16-week Stage 1 were randomized to either Q2W rademikibart (n=113) or Q4W rademikibart (n=112) arms.
Patients who did not achieve EASI-50 (non-responders) were assigned to an open-label Q2W rademikibart arm (n=86).
An efficacy analysis ...